Provided by Tiger Trade Technology Pte. Ltd.

NewMarket

627.33
-1.7900-0.28%
Post-market: 627.330.00000.00%16:34 EDT
Volume:55.14K
Turnover:34.64M
Market Cap:5.90B
PE:14.12
High:635.79
Open:625.34
Low:623.94
Close:629.12
52wk High:875.97
52wk Low:510.07
Shares:9.40M
Float Shares:7.78M
Volume Ratio:0.33
T/O Rate:0.71%
Dividend:11.50
Dividend Rate:1.83%
EPS(TTM):44.44
EPS(LYR):44.44
ROE:25.85%
ROA:11.27%
PB:3.32
PE(LYR):14.12

Loading ...

NewMarket Corp FY2025 interest and financing expenses drop to USD 40 million, down 29%

Reuters
·
Feb 13

NewMarket Corp. Down Nearly 13%, on Pace for Largest Percent Decrease Since February 2012 -- Data Talk

Dow Jones
·
Feb 13

NewMarket Q4 Earnings, Sales Fall

MT Newswires Live
·
Feb 12

NewMarket posts FY 2025 net income of USD 419 million

Reuters
·
Feb 12

Earnings Flash (NEU) NewMarket Posts Q4 EPS of $8.65

MT Newswires Live
·
Feb 12

NewMarket Q4 revenue declines

Reuters
·
Feb 12

NewMarket Q4 EPS $8.65 Down From $11.56 YoY, Sales $635.403M Down From $654.647M YoY

Benzinga
·
Feb 12

BRIEF-NewMarket Q4 Net Income USD 81.285 Million

Reuters
·
Feb 12

NewMarket Q4 Segment Operating Profit USD 111.574 Million

THOMSON REUTERS
·
Feb 12

NewMarket Q4 Sales USD 635.403 Million

THOMSON REUTERS
·
Feb 12

NewMarket Q4 EPS USD 8.65

THOMSON REUTERS
·
Feb 12

Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch

Simply Wall St.
·
Feb 06

Neuren Pharmaceuticals (ASX:NEU) Is Down 16.1% After EMA Setback on Trofinetide Approval Prospects

Simply Wall St.
·
Feb 04

Earning Preview: NewMarket revenue is expected to be stable, and institutional views tilt neutral to cautious

Earnings Agent
·
Feb 04

Neuren Pharmaceuticals (ASX:NEU) Valuation Check After DAYBUE Growth Outlook And Pipeline Progress

Simply Wall St.
·
Jan 16

NewMarket Corporation Schedules Conference Call and Webcast to Review Financial Results

Reuters
·
Jan 16

Nyse Order Imbalance 18833.0 Shares on Buy Side

THOMSON REUTERS
·
Jan 16

NewMarket Corporation's (NYSE:NEU) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Simply Wall St.
·
Jan 04

Neuren Pharmaceuticals (ASX:NEU): Valuation Check After FDA Approval of DAYBUE STIX Rett Syndrome Powder Formulation

Simply Wall St.
·
Dec 16, 2025

Does Neuren Pharmaceuticals' (ASX:NEU) Pre-IND Delay Hint At Deeper Pipeline Timing Trade-Offs?

Simply Wall St.
·
Dec 12, 2025